Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 3/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8319708 | 0.74 | DYRK1B (0.40) | DYRK1ADYRK1BPIK3CAMTORCHEK1 | |
| SCHEMBL21806796 | 0.71 | DYRK1A (0.38) | DYRK1ADYRK1BCHEK1AURKACSF1R | |
| SCHEMBL8328800 | 0.71 | DYRK1A (0.52) | DYRK1ADYRK1BPIK3CACHEK1AURKA | |
| SCHEMBL15726869 | 0.71 | PIM1 (0.45) | DYRK1ADYRK1BCHEK1AURKACSF1R | |
| SCHEMBL8327596 | 0.71 | DYRK1A (0.38) | DYRK1ADYRK1BCHEK1AURKACSF1R | |
| SCHEMBL23199596 | 0.71 | DYRK1B (0.45) | DYRK1ADYRK1BCHEK1AURKACSF1R | |
| SCHEMBL4553675 | 0.70 | KDM4E (0.34) | — | |
| SCHEMBL29402652 | 0.70 | KDM4E (0.34) | — | |
| SCHEMBL1271229 | 0.68 | DYRK1B (0.58) | DYRK1ADYRK1BPIK3CAMTORGSK3A | |
| SCHEMBL3433362 | 0.67 | DYRK1A (0.33) | DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3894413-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | claimed |
| EP-3893881-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | claimed |
| WO-2020123271-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | claimed |
| WO-2020123272-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3634964-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3894413-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3893881-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123272-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123271-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3634964-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018226771-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | DYRK1A 1488/4885DYRK1B 1906/4885PIK3CA 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.